Quarterly ResultMay 8, 2026, 07:11 AM
Kiora Pharmaceuticals Q1 Net Loss $(2.42)M; Cash Runway to Late 2028
AI Summary
Kiora Pharmaceuticals reported a net loss of $(2.42) million for the first quarter of 2026, an increase from $(2.19) million in the prior year, with basic net loss per common share at $(0.58). Despite increased operating expenses and cash used in operations, the company's cash and cash equivalents rose to $10.96 million. Following a $5 million financing transaction in April 2026, Kiora Pharmaceuticals anticipates having sufficient cash to fund its planned operations into late 2028.
Key Highlights
- Net Loss for Q1 2026 was $(2.42) million, up from $(2.19) million in Q1 2025.
- Basic Net Loss per Common Share was $(0.58) in Q1 2026, compared to $(0.52) in Q1 2025.
- Cash and Cash Equivalents increased to $10.96 million at March 31, 2026, from $8.70 million at Dec 31, 2025.
- Short-Term Investments decreased to $2.92 million at March 31, 2026, from $8.39 million at Dec 31, 2025.
- Net Cash Used in Operating Activities was $(3.16) million in Q1 2026, up from $(2.70) million in Q1 2025.
- Received $5 million cash proceeds from a financing transaction in April 2026.
- Company expects sufficient cash to fund operations into late 2028.
- Total Operating Expenses increased to $2.51 million in Q1 2026 from $2.33 million in Q1 2025.